Press Releases

Date Headline
11/19/2021
Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)
 Summary
Full presentation available December 8 at 5:00 pm Central Time (CT) VANCOUVER, British Columbia --(BUSINESS WIRE)--Nov. 19, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract  Continue Reading
11/9/2021
Zymeworks Names Neil Josephson, M.D., Chief Medical Officer
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Nov. 9, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Neil Josephson , M.D., who has been serving as the company’s interim Chief Medical Officer (CMO)  Continue Reading
11/9/2021
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
 Summary
HERIZON-GEA-01 study is now open and enrolling patients to evaluate zanidatamab and chemotherapy with or without tislelizumab, versus standard of care Phase 2 data demonstrate potential benefit of zanidatamab in first-line GEA, with response rates and durability that compare favorably to both  Continue Reading
11/8/2021
Zymeworks to Present at Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Nov. 8, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming investor conferences.  Continue Reading
11/3/2021
Zymeworks Reports 2021 Third Quarter Financial Results
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Nov. 3, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the third quarter ended September 30, 2021 .  Continue Reading
10/26/2021
Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Oct. 26, 2021-- Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will host a conference call and webcast to provide details related to the launch of its  Continue Reading
10/5/2021
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
 Summary
VANCOUVER, British Columbia & SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 5, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Holdings Inc. (NASDAQ: ALXO), a clinical-stage immuno-oncology company  Continue Reading
9/16/2021
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
 Summary
Confirmed objective response rate (cORR) of 75% overall and   93% for the proposed Phase 3 regimen (zanidatamab + CAPOX/FP) Median duration of response (mDOR) of 16.4 months and median progression free survival (mPFS) of 12 months Data support zanidatamab + chemotherapy as the foundation of a  Continue Reading
9/12/2021
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
 Summary
Abstract data demonstrate encouraging antitumor activity in first-line GEA Full ESMO presentation available September 16 at 8:30 am CEST , 2:30 am ET Conference call and webcast with principal investigator, Dr. Geoffrey Ku , on September 16 at 7:30 am ET VANCOUVER, British Columbia --(BUSINESS  Continue Reading
8/4/2021
Zymeworks Reports 2021 Second Quarter Financial Results
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Aug. 4, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the second quarter ended June 30, 2021 .  Continue Reading
Displaying 1 - 10 of 27
Copyright 2021 , Zymeworks Inc.